Magazine Article | May 3, 2021

First In Line: FDA Vs. EMA Biopharma Approval Times

Source: Life Science Leader

By Brendan Wang & Christian Thienel

The majority of biopharma companies emphasize the U.S. market as the pillar of their business case and commercial strategy. Conventional wisdom is that price potential is significantly higher in the U.S., and the lack of time-intensive healthcare technology assessment (HTA) processes such as those seen in Europe are the key drivers of this phenomenon. However, often lost in this discussion is whether the regulatory agencies themselves have a major impact — namely whether there is any difference in approval timelines between the FDA and EMA.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader